COVID-19 Update

The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

More technologies and treatments are emerging for COVID-19—along with new variants.

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

October 22, 2021

Pfizer and BioNTech’s Phase III trial demonstrated 95.6% booster efficacy relative to participants who received placebo.

October 22, 2021

EMA's CHMP has approved two new manufacturing sites and a ready-to-use formulation of Comirnaty.

October 22, 2021

EMA has started its evaluation of further expanded use of Comirnaty in children aged between five years and 11 years old.

October 22, 2021

UK government has secured two new antiviral treatments for COVID-19, which may be rolled out in a national clinical study before the end of 2021.

October 21, 2021

In addition to allowing booster shots of the Moderna and J&J vaccines, FDA approved heterologous booster shots.

October 15, 2021

Advanced powder testing is a useful tool to differentiate materials and optimize the supply chain.

October 14, 2021

Roche has submitted a marketing authorization application to EMA for Ronapreve (casirivimab/imdevimab) as a treatment for COVID-19.

October 14, 2021

EMA has halted the rolling review of CureVac's COVID-19 candidate, CVnCoV, due to the company withdrawing from the process.

October 13, 2021

Smiths Detection has confirmed that the Bioflash air sampler can detect Beta, Gamma, Kappa, Delta, and Delta plus variants.

October 12, 2021

AstraZeneca reports that its combination antibody therapy, AZD7442, reduced chances of severe COVID-19 or death by as much as 67%.